Organism: Homo sapiens
Gene: 39018_at
Selected probe(set): 201403_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39018_at (201403_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):3.2273207
Number of Samples:2 / 3

Experimental	glioma study 16 (BS-149)
	Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):3.0400133
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.727703
Number of Samples:8 / 9

Experimental	hepatocyte (ESC)
	Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control	Hep-G2
	Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

Relative Expression (log2-ratio):2.6537676
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):-2.5510054
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Relative Expression (log2-ratio):2.4609013
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (NOD2L/TLR/1L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control	monocyte activation study 1 (NOD2L/TLR/1L; 6h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

Relative Expression (log2-ratio):2.335288
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (TLR/1L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control	monocyte activation study 1 (TLR/1L; 6h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

Relative Expression (log2-ratio):2.2987003
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (NOD2L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control	monocyte activation study 1 (NOD2L; 6h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.

Relative Expression (log2-ratio):-2.260522
Number of Samples:58 / 74

Experimental	precursor-B-ALL study 1 (t(12;21)(p12,q22))
	Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-2.1991444
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.